文献速递青光眼神经眼科

替米沙坦减少实验性青光眼小鼠的轴突变性

Telmisartan Reduces Axon Degeneration in Mice With Experimental Glaucoma.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2020-01-01

该研究在微珠诱导眼压升高的C57BL/6J小鼠青光眼模型中,比较替米沙坦喂养与对照喂养对视网膜神经节细胞轴突的保护作用。结果显示两组眼压升高程度和持续时间相似,但替米沙坦组视神经轴突丢失和变性轴突比例均显著低于对照组,提示替米沙坦具有神经保护作用。

要点

  • 替米沙坦喂养不改变微珠注射诱导的眼压升高程度和持续时间。
  • 替米沙坦组视神经轴突丢失百分比显著低于对照组。
  • 替米沙坦组变性轴突比例增加显著低于对照组。

核心结论

  • 微珠注射升高眼压导致对照喂养小鼠视网膜神经节细胞轴突丢失,替米沙坦治疗在很大程度上防止了该丢失,提示替米沙坦具有神经保护作用。

研究设计与样本

  • 研究使用3月龄C57BL/6J小鼠,右眼前房注射聚苯乙烯微珠诱导眼压升高,左眼作为对侧对照。
  • 从微珠注射当天起,小鼠分别维持含替米沙坦或不含替米沙坦的固体饲料喂养。
  • 视神经轴突总数通过人工和AxonJ自动化方法确定,变性轴突通过人工计数。

主要发现

  • 微珠注射诱导的眼压升高在对照喂养和替米沙坦喂养小鼠中幅度和持续时间相似。
  • 未注射眼接受替米沙坦治疗的小鼠眼压降低5.8%(P = 0.0027)。
  • 人工法测定轴突丢失在对照组为9.5%,替米沙坦组为1.8%(P = 0.044);自动化法分别为14.2%和2.9%(P = 0.0375)。
  • 微珠注射眼视神经中变性轴突百分比增加,对照组为49.0%,替米沙坦组为-0.58%(P = 0.0019)。

临床怎么用

  • 在眼压升高的小鼠青光眼模型中,替米沙坦喂养可减少视神经轴突丢失和变性轴突比例。
  • 替米沙坦对未注射眼眼压有轻度降低作用(降低5.8%,P = 0.0027)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to determine if treatment with telmisartan, an angiotensin II type 1 receptor blocker (ARB), protects against retinal ganglion cell (RGC) degeneration in a mouse glaucoma model with induced elevation of intraocular pressure (IOP). METHODS: IOP elevation was induced by injection of polystyrene microbeads into the anterior chamber of the right eye of 3-month-old C57BL/6J mice, with the left eye serving as contralateral control. Starting the day of microbead injection, mice were maintained on solid food pellets with or without incorporated telmisartan. IOP was measured by Tono Lab tonometry prior to and weekly after microbead injection. Twelve weeks postinjection, mice were euthanized to obtain optic nerves for analysis of RGC axons. The total numbers of optic nerve axons were determined manually and automatedly using AxonJ. Degenerating axons were counted manually. RESULTS: IOP elevation induced by microbead injection was similar in magnitude and duration in vehicle and telmisartan-fed mice, although IOP was reduced 5.8% in uninjected mice treated with telmisartan (P = 0.0027). Axon loss determined by manual and automated methods was greater in vehicle compared to telmisartan-treated mice (manual: 9.5% vs. 1.8%, P = 0.044; automated: 14.2% vs. 2.9%, P = 0.0375). An increase in the percent of axons undergoing degeneration was observed in nerves from microbead-injected eyes that was greater in vehicle-treated compared to telmisartan-treated mice (49.0% vs. -0.58%, P = 0.0019). CONCLUSIONS: Elevation of IOP by microbead injection led to loss of RGC axons in vehicle-treated mice that was largely prevented by telmisartan treatment, suggesting a neuroprotective effect of telmisartan.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Hazlewood RJ, Kuchtey J, Wu HJ, et al. Telmisartan Reduces Axon Degeneration in Mice With Experimental Glaucoma. Invest Ophthalmol Vis Sci. 2020. PMID: 32460313. doi:10.1167/iovs.61.5.51

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。